FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
FundaMental Pharma GmbH (‘FundaMental’ or ‘The Company’), a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director. Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant.
Spacing rules in the brain: Novel compounds that act as molecular spacers in the brain prevent neurodegeneration
High-Tech Gründerfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg University.
New class of highly effective inhibitors protects agains neurodegeneration
Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents
Protecting the neuronal architecture
Heidelberg researchers investigate new approaches to treating neurodegenerative diseases